Cancer feature: cnaPANCAN18

ADCYAP1 AFG3L2 ANKRD12 ANKRD62 AP005482.1 APCDD1 ARHGAP28 C18orf42 C18orf56 C18orf64 CEP192 CEP76 CETN1 CHMP1B CIDEA CLUL1 COLEC12 DLGAP1 EMILIN2 ENOSF1 EPB41L3 FAM210A GNAL IMPA2 L3MBTL4 LAMA1 LDLRAD4 LPIN2 LRRC30 MC2R MC5R METTL4 MPPE1 MYL12A MYL12B MYOM1 NAPG NDC80 NDUFV2 PIEZO2 POTEC PPP4R1 PSMG2 PTPN2 PTPRM RAB12 RAB31 RALBP1 RNMT SEH1L SLMO1 SMCHD1 SOGA2 SPIRE1 TGIF1 TMEM200C TUBB6 TWSG1 TXNDC2 TYMS VAPA YES1 ZBTB14 ZNF519

Known Driver Genes: None

Copy number alternation: gain

Dactinomycin

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer